Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers

NCT01929226 is registered in ClinicalTrials.gov with Elusys Therapeutics as lead sponsor.

NCT NCT01929226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01929226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Lead sponsor
Elusys Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
July 9, 2013
Completion date
November 29, 2013
Enrollment
280 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inhalational anthrax